AUTL Autolus Therapeutics Ltd - ADR

$AUTL New to this ticker. can ppl kindly do a summary of upcoming catalysts and outlook?

$AUTL The recent pullback was simply a reversion to the mean. AUTL bounced right off the mean and is now heading higher again. As I mentioned in previous posts, the Standard Deviation line has reversed a years-long downtrend and is now moving higher. That matters. Stocks naturally tend to revert toward their mean, so as the mean continues to rise, it creates a higher baseline for the stock. We already know Itan tends to sandbag expectations. If the next earnings report delivers another beat, I believe $3+ going into year-end is very much in play—especially with no meaningful tax-loss selling pressure and the potential for a new 52-week high.

$AUTL 🔥 $AUTL's Management Isn't Looking to License: They're Going to Dominate the Lupus Market Independently While the competition outsources to labs and suffers delays, Autolus's scientific team has vertically integrated from discovery to distribution. Management has proven its ability to move drugs from the UCL lab to FDA approval. Buying $AUTL means buying the best science in Europe! 👑🌍

$AUTL I've been tracking AUTL for three years. They have executed well, clinical trials going well and now we can measure them from a business standpoint. The bears are betting on CAR T not scaling well and dilution. AUTL has so far answered those nay sayers. We will see what Q4 brings. If AUTL continues to execute in late 2026 as they did in early 2026 bulls are in great shape going into 2027. Analysts understand this and bulls understand this. The risk is the clinical trials for lupus going South, factory disruption, spending issues or some other negative catalyst. Traders will play, sowing doubt that will send the weak hearted out the door, but there are a large group of shareholders that will not be moved. Biotech has a high reward but carries a lot of risk. Not for the faint of heart. My opinion as usual not investment advice. I assume NANANANANONONO will create a new meme for me after this post.

$AUTL Caribou halts its allogeneic CAR T programs. Not a direct competitor but they had a CD19-targeting program. One more allogeneic program to fold and demonstrate how difficult to make it in this field.

$AUTL Itin sandbagging rev guidance more than IOVA. Plus lupus data. Patiently waiting for $9.

$AUTL ⏳ Next stop: Lupus follow-up data release at year-end With over 80 active treatment centers and ongoing expansion in Europe, the market has yet to fully price in the upcoming data on durable response and clear immunity in the high-dose cohort. A clear opportunity ahead of the Q4 clinical update! 🌋📊

$AUTL market makers have their racket going. They increase the bid as it gets to 1.80 and increase the ask as it gets to 1.95. Playing both ends, works well on a low float biotech until news/catalyst arrives. They don't care, they make money off other people's money on the spread. Probably even more so with AI, they don't even have to watch it. You see a lot of volume early in the mornings as they set it up and late in the evening when they close it out. Don't like it but its a fact nowadays and will increase as AI Bots/agents take charge of the trading. I'll just stay long and not let them shake the coconuts out of my tree.

$AUTL 🔬 Why Obe-cel Will Outperform the Competition in Autoimmunity (0% ICANS) While other CAR-T therapies send patients to the ICU due to neurotoxicity or severe CRS, Obe-cel registers 0% ICANS and 0% severe CRS thanks to its rapid dissociation engineering. Outpatient administration = Maximum adoption by rheumatologists. Deep remission efficacy without destructive side effects! 🧬🚀

$AUTL IMO/Not advice...what would it take for AUTL to get rerated similar to what happened to IOVA: ALL franchise proving it can fund itself Beat / raise again on AUCATZYL Gross margin grinding toward the 65–70% peak Clearer path that they don’t need another large equity raise before Q4 2027 That shifts the stock from “cash-burn biotech” to “commercial compounder.” Autoimmune data that looks competitive. Q4 2026: longer CARLYSLE SLE follow-up (already slated for ACR) YE 2026: initial ALARIC amyloidosis data Q1 2027: first BOBCAT progressive MS look; fuller MS data 2H 2027 A clean safety + durability signal in SLE/LN or a surprising MS dataset is what would make people pay for the pipeline instead of only ALL sales. Pediatric ALL (CATULUS) Enrollment done YE 2026, pivotal-style data YE 2027, possible 2028 peds launch. That’s a real label expansion, not a science experiment. Capital-structure relief If revenue + the $15M opex save + the credit facility make dilution look optional

$AUTL "The next data update from the Phase 1 CARLYSLE trial with patients in SLE has been submitted for presentation at the American College of Rheumatology (ACR) annual meeting in the fourth quarter of 2026." The meeting dates are November 6-11.

$AUTL Another 2,700 shares added today; brought my average down a penny to $2.72 😂. Hoping for strong SLE and MS data to give us a kick 🍀

$AUTL there is nothing unusually about this pullback. all it did was revert back to the MEAN. just like I pointed out in a previous post. Every stock sooner of later ALWAYS reverts back to the MEAN. I'm just surprised it happened this fast. AUTL was at +3 which had no chance of continuing a move higher in the short term and you can see AUTL trading right to the +3 SD price. I dont think we go much lower and we're setting up nicely for the next leg up as the Mean is rising every day.

$AUTL looking at the Volume Profile, price is just ripping through these low volume nodes. Not concerned, I know what I own and still holding

$AUTL hedge fund games. Three weeks before earnings they’ll flip and the stock will fly. Never fails.

$AUTL in even deeper this time for some crazy reason. I have some ties to this stock and I just can’t shake it. I refuse to walk away without a 5x return….might bite me.

$AUTL Only painful if you need to sell. Whole sector has had downward pressure applied to it. I can wait it out. Adding to positions that have taken more downside than their peers.

$AUTL ACR Abstract 2216 — CARLYSLE 2026⁠ The big ones: 10/12 (83.3%) achieved DORIS remission WITHOUT background immunosuppressants. All 12/12 achieved either LLDAS or DORIS. ZERO renal flares. Of the 9 lupus-nephritis patients, 7/9 normalized urine protein/creatinine to ≤0.5 mg/mg. Among LN patients reaching month 6, 5/8 (63%) achieved complete renal All patients achieved complete B-cell depletion. Of the six patients with B-cell reconstitution, 5/6 had >90% transitional/naïve B cells when their B cells returned. Meanwhile, in that adult 50M cohort: median CAR transgene persistence = only 3 months. And those six adults now have median 15.2 months follow-up, range 12.3–20.1 months. So yes. CAR-T disappears ~3 months → B cells subsequently return → >90% of returning B cells are transitional/naïve in 5/6 → clinical remission/low disease activity is being observed deep into follow-up.

$AUTL Q3 wraps up tomorrow. Another sales guidance surprise might be in store very soon. 👀

$AUTL look at $IOVA raising guidance like Autolus. Doctors are really adopting the new cancer treatments and it’s starting to show. Great to see and to be invested in life changing stocks is rewarding in more ways than one.